CA
EW icon

Crewe Advisors’s Edwards Lifesciences EW Stock Holding History

Crewe Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.34K Buy
+48
New +$4.02K ﹤0.01% 907
2025
Q2 		– Sell
-4
Closed -$290 – 772
2025
Q1 		$290 Buy
+4
New +$286 ﹤0.01% 675
2024
Q4 		– Sell
-290
Closed -$19.1K – 701
2024
Q3 		$19.1K Hold
290
– – ﹤0.01% 412
2024
Q2 		$26.8K Hold
290
– – ﹤0.01% 496
2024
Q1 		$27.7K Buy
+290
New +$24.4K ﹤0.01% 447
2023
Q2 		– Sell
-108
Closed -$8.94K – 922
2023
Q1 		$8.94K Sell
108
-121
-53% -$9.51K ﹤0.01% 570
2022
Q4 		$17.1K Sell
229
-144
-39% -$11.1K ﹤0.01% 450
2022
Q3 		$31K Buy
373
+76
+26% +$7.31K 0.01% 385
2022
Q2 		$28K Buy
+297
New +$30.7K 0.01% 363
2021
Q4 		– Sell
-30
Closed -$3K – 422
2021
Q3 		$3K Hold
30
– – ﹤0.01% 330
2021
Q2 		$3K Hold
30
– – ﹤0.01% 369
2021
Q1 		$3K Hold
30
– – ﹤0.01% 393
2020
Q4 		$3K Hold
30
– – ﹤0.01% 382
2020
Q3 		$2K Buy
+30
New +$2.34K ﹤0.01% 499

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Crewe Advisors's EW Position: Q2 2026 in Review

Crewe Advisors opened a new position in Edwards Lifesciences (EW) in Q2 2026: 48 shares worth $4.34K. The stake represents ﹤0.01% of the portfolio and ranks #907 among its holdings. This is a return to the name: Crewe Advisors previously reported a position in EW as recently as Q1 2025.

Crewe Advisors first reported a position in EW in Q3 2020 and has held it in 14 quarters since. The position peaked at $31K in Q3 2022. 1,335 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Crewe Advisors held 48 shares of Edwards Lifesciences worth $4.34K as of Q2 2026.
  • Edwards Lifesciences was a new Crewe Advisors position in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #907 holding.
  • Crewe Advisors first reported a position in Edwards Lifesciences in Q3 2020 and has held it in 14 quarters since.
  • Crewe Advisors's Edwards Lifesciences position peaked at $31K in Q3 2022.
  • 1,335 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.